Literature DB >> 7515053

Localization of vitronectin binding domain in plasminogen activator inhibitor-1.

D A Lawrence1, M B Berkenpas, S Palaniappan, D Ginsburg.   

Abstract

Plasminogen activator inhibitor type 1 (PAI-1) is the rapid physiologic inhibitor of tissue-type plasminogen activator and urokinase-type plasminogen activator (uPA). In plasma and the extracellular matrix, PAI-1 is associated with the adhesive glycoprotein vitronectin. In order to characterize the PAI-1 structural domain responsible for binding to vitronectin, the segment of the PAI-1 cDNA encoding amino acids 13-147 (nucleotides 248-650) was randomly mutagenized and subcloned into a bacterial expression vector containing the mature PAI-1 coding sequence. Recombinant PAI-1 mutants were expressed in Escherichia coli and bacterial lysates assayed in duplicate for uPA inhibitory activity and vitronectin binding. Of 190 clones screened, six consistently demonstrated decreased vitronectin binding relative to uPA inhibitory activity. DNA sequence analysis of four of these clones identified 10 unique missense mutations, all located between base pairs 298 and 641, with each clone containing between one and four substitutions. Each substitution was expressed independently by site-directed mutagenesis and again analyzed for uPA inhibitory activity and vitronectin binding. Five point mutations that selectively disrupt vitronectin binding were identified. All 5 residues are located on the exterior of the PAI-1 structure. These findings appear to define a complex binding surface that bridges alpha-helices C and E to beta-strand 1A and includes amino acids 55, 109, 110, 116, and 123. These results suggest that vitronectin binding may stabilize the active conformation of PAI-1 by restricting the movement of beta-sheet A and thereby preventing insertion of the reactive center loop.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515053

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Identification of a PAI-1-binding site within an intrinsically disordered region of vitronectin.

Authors:  Yuzhuo Chu; Joel C Bucci; Cynthia B Peterson
Journal:  Protein Sci       Date:  2019-11-20       Impact factor: 6.725

2.  Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.

Authors:  K W Rodenburg; L Kjoller; H H Petersen; P A Andreasen
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

Review 3.  The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.

Authors:  Marta Helena Kubala; Yves Albert DeClerck
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

4.  A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.

Authors:  Yufeng Huang; Masashi Haraguchi; Daniel A Lawrence; Wayne A Border; Ling Yu; Nancy A Noble
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

5.  PAI1 stimulates assembly of the fibronectin matrix in osteosarcoma cells through crosstalk between the alphavbeta5 and alpha5beta1 integrins.

Authors:  Daniel Vial; Paula J McKeown-Longo
Journal:  J Cell Sci       Date:  2008-04-29       Impact factor: 5.285

6.  Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization.

Authors:  S M Nordstrom; S M Carleton; W L Carson; M Eren; C L Phillips; D E Vaughan
Journal:  Bone       Date:  2007-08-17       Impact factor: 4.398

7.  A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity.

Authors:  Christine R Schar; Grant E Blouse; Kenneth H Minor; Cynthia B Peterson
Journal:  J Biol Chem       Date:  2008-01-03       Impact factor: 5.157

8.  Functional structure of the somatomedin B domain of vitronectin.

Authors:  Aiwu Zhou
Journal:  Protein Sci       Date:  2007-06-13       Impact factor: 6.725

9.  Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands.

Authors:  Shih-Hon Li; Natalia V Gorlatova; Daniel A Lawrence; Bradford S Schwartz
Journal:  J Biol Chem       Date:  2008-04-24       Impact factor: 5.157

10.  Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro.

Authors:  D T Eitzman; W P Fay; D A Lawrence; A M Francis-Chmura; J D Shore; S T Olson; D Ginsburg
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.